BioTuesdays

Author - Melane Sampson

VYNE and Yarrow announce merger agreement

VYNE Therapeutics (NASDAQ: VYNE) has announced that it has entered into a merger agreement with closely held Yarrow Bioscience, with the combined companies expected to operate as Yarrow Bioscience under the ticker...

ENvue Logo

ENvue appoints David Johnson as chairman

ENvue Medical (NASDAQ: FEED) announced the appointment of David Johnson as chairman of the board. Mr. Johnson is a seasoned healthcare executive and board leader with more than 30 years of experience across the medical...

Cadrenal Therapeutics logo

Cadrenal acquires VLX-1005 for patients with HIT

Cadrenal Therapeutics (NASDAQ: CVKD) has announced the acquisition of VLX-1005—a first-in-class, Phase 2 12-LOX inhibitor—along with additional 12-lipoxygenase (12-LOX) assets from closely held Veralox Therapeutics, for...